Paige

# Paige: AI-Powered Cancer Diagnostics

High-Level Overview

Paige is an artificial intelligence company specializing in digital pathology and cancer diagnostics.[1][2] Founded in 2017, Paige develops AI-assisted applications designed to help pathologists detect, classify, and characterize cancer with greater precision and efficiency.[1][2] The company serves healthcare professionals and life sciences organizations across 45 countries, working with over 800 laboratory and medical institutions.[1]

Paige's core mission centers on enhancing the precision and impact of cancer diagnostics by equipping healthcare professionals with AI tools that navigate the molecular and cellular complexities of cancer.[1] The company addresses a critical pain point in pathology: the time-intensive nature of manual tissue analysis and the growing workload pressures on pathologists. By automating detection, grading, and biomarker discovery tasks, Paige enables faster turnaround times while maintaining diagnostic accuracy.[2][4]

Origin Story

Paige was founded in 2017 and is based in New York.[2] The company built its foundation on pathology expertise, combining advanced AI capabilities with insights from world-renowned medical and scientific experts.[1] A pivotal achievement came with the development of the first FDA-cleared AI application in pathology, a significant regulatory milestone that validated the clinical utility of its technology.[5]

The company's early traction was driven by substantial data accumulation. Paige assembled one of the largest and most diverse digital pathology datasets available—comprising 25 million accessible pathology slides, data from 350,000 patients, and 200,000 cases with outcome and genomic information.[1] This dataset spans diverse genders, races, ethnicities, and 45 countries, providing the foundation for training robust, generalizable AI models.[5]

Core Differentiators

Unparalleled Dataset Scale and Diversity

• Access to 25 million digitized pathology slides with associated clinical and molecular data[1]
• Training data spanning 350,000 patients across 45 countries with diverse demographic representation[1]
• 200,000 cases with outcome and genomic data enabling validation of predictive capabilities[1]

Advanced Foundation Models

• Developed the first million-slide foundation model for cancer, enabling broader research applications[5]
• Multiple proprietary foundation models (Virchow, Virchow2, Virchow2G, PRISM) that set new standards for size, scale, and performance[4]
• Models trained on over 1.5 million slides for the PanCancer Suite[4]

Comprehensive Product Portfolio

• Paige Prostate: CE-marked clinical-grade software for prostate cancer detection, grading, and quantification; demonstrated reduced diagnosis time and lower unnecessary test rates[2]
• Paige GI Suite: AI applications for gastrointestinal tract pathology across benign and malignant conditions[4]
• Paige PanCancer Suite: Multi-tissue diagnostic capabilities including rare cancers[4]
• Paige Alba™: Multi-modal co-pilot designed to revolutionize pathology workflows and precision medicine[1][4]

Regulatory Validation

• First FDA-cleared AI application in pathology, establishing clinical credibility[5]
• Real-world validation through partnerships, including NHS-funded prospective evaluation in the UK[2]

Role in the Broader Tech Landscape

Paige operates at the intersection of three powerful trends: the digitization of pathology, the maturation of foundation models for specialized domains, and the shift toward precision medicine in oncology.

The company is riding the wave of digital pathology adoption, where traditional microscopy-based workflows are transitioning to whole-slide imaging and computational analysis.[1][2] This shift creates both opportunity and urgency—pathology labs face mounting workload pressures as cancer incidence rises and diagnostic complexity increases.

Paige's development of domain-specific foundation models represents a broader industry trend toward building large-scale, pre-trained models for specialized applications rather than relying solely on general-purpose AI.[4] By training on millions of pathology slides, Paige has created models that understand cancer's visual and molecular signatures in ways generic AI systems cannot.

The company's emphasis on data diversity and geographic representation also reflects growing recognition that AI systems must be trained on representative populations to avoid perpetuating diagnostic disparities. This positions Paige favorably as healthcare systems increasingly prioritize equitable AI deployment.

Quick Take & Future Outlook

Paige has established itself as a leader in computational pathology by combining regulatory validation, substantial proprietary datasets, and advanced foundation models. The company's trajectory suggests continued expansion across cancer types and geographic markets, with Paige Alba™ representing an evolution toward more integrated, multi-modal diagnostic support.

The acquisition by Tempus (announced in the search results) signals confidence in Paige's technology and market position, enabling the company to scale its dataset further and accelerate commercialization.[5] As precision oncology becomes standard care, Paige's ability to extract molecular insights directly from tissue samples—without additional testing—positions it as a critical infrastructure layer in modern cancer care.

The key question ahead is whether Paige can maintain its technical leadership as competitors enter the digital pathology space, and whether its foundation models can be successfully adapted for drug discovery and development applications beyond diagnostic support.